[Form 4] MARAVAI LIFESCIENCES HOLDINGS, INC. Insider Trading Activity

Rhea-AI Filing Summary

Maravai LifeSciences Holdings, Inc. (MRVI)4,300 shares of Class A Common Stock at $1.79 per share through the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The transaction was reported as exempt under Rule 16b-3. Following this purchase, the insider beneficially owns 477,907 shares of Class A Common Stock in direct ownership.

11/18/2025 - 04:17 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dolan Christine

(Last) (First) (Middle)

C/O MARAVAI LIFESCIENCES HOLDINGS, INC.

10770 WATERIDGE CIRCLE, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MARAVAI LIFESCIENCES HOLDINGS, INC. [ MRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	11/14/2025		A(1)	V	4,300	A	$1.79	477,907	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 4,300 shares of Class A Common Stock was exempt pursuant to Rule 16b-3.

Remarks:

	/s/ Kurt Oreshack, by power of attorney for Christine Dolan	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Maravai LifeSciences (MRVI) report in this Form 4?

The filing reports that a company officer acquired 4,300 shares of Maravai LifeSciences Holdings, Inc. Class A Common Stock on 11/14/2025.

At what price were the MRVI shares acquired in this insider purchase?

The insider purchased the Class A Common Stock at a price of $1.79 per share.

What is the total MRVI share ownership of the insider after this transaction?

After the reported transaction, the insider beneficially owns 477,907 shares of Maravai LifeSciences Holdings, Inc. Class A Common Stock in direct ownership.

Under what plan were the Maravai (MRVI) shares acquired by the insider?

The 4,300 shares were acquired pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan.

Was the MRVI insider share acquisition exempt from Section 16(b) short-swing profit rules?

Yes. The acquisition of the 4,300 shares of Class A Common Stock was reported as exempt pursuant to Rule 16b-3.

What is the relationship of the reporting person to Maravai LifeSciences (MRVI)?

The reporting person is an officer of Maravai LifeSciences Holdings, Inc., as indicated in the relationship section of the form.

When was this MRVI Form 4 insider transaction signed?

The Form 4 was signed on 11/18/2025 by /s/ Kurt Oreshack, by power of attorney for Christine Dolan.